BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38009481)

  • 1. Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFR
    Xu S; Zhou Z; He J; Guo J; Huang X; An Y; Pan Q; Xu S; Zhu W
    Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300460. PubMed ID: 38009481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the Overcoming EGFR
    Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
    ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel aminopyrimidine derivatives for the treatment of mutant NSCLC.
    Hu L; Shi S; Song X; Ma F; Ji O; Qi B
    Eur J Med Chem; 2024 Feb; 265():116074. PubMed ID: 38142512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
    Liu Y; Lai M; Li S; Wang Y; Feng F; Zhang T; Tong L; Zhang M; Chen H; Chen Y; Song P; Li Y; Bai G; Ning Y; Tang H; Fang Y; Chen Y; Lu X; Geng M; Ding K; Yu K; Xie H; Ding J
    Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR
    Fang H; Wu Y; Xiao Q; He D; Zhou T; Liu W; Yang CH; Xie Y
    Bioorg Med Chem Lett; 2022 Sep; 72():128729. PubMed ID: 35413415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of phosphoroxy quinazoline derivatives as potential EGFR
    Guo Y; Gao B; Gao P; Wang Y; Gou S
    Bioorg Med Chem; 2023 Jul; 90():117338. PubMed ID: 37269687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
    Chen ZW; Lin G; Shih HJ; Wu CE
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).
    Zhang Y; Tong L; Yan F; Huang P; Zhu CL; Pan C
    Bioorg Chem; 2024 Jun; 147():107394. PubMed ID: 38691906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.
    Du Y; Chen Y; Wang Y; Chen J; Lu X; Zhang L; Li Y; Wang Z; Ye G; Zhang G
    Mol Cancer Ther; 2022 Jul; 21(7):1060-1066. PubMed ID: 35499406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
    Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
    Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.
    Chen H; Lai M; Zhang T; Chen Y; Tong L; Zhu S; Zhou Y; Ren X; Ding J; Xie H; Lu X; Ding K
    J Med Chem; 2022 May; 65(9):6840-6858. PubMed ID: 35446588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
    Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
    J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance.
    Zhu Y; Ye X; Shen H; Li J; Cai Z; Min W; Hou Y; Dong H; Wu Y; Wang L; Wang X; Xiao Y; Yang P
    J Med Chem; 2023 Nov; 66(21):14633-14652. PubMed ID: 37885208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.
    Wang C; Wang X; Huang Z; Wang T; Nie Y; Yang S; Xiang R; Fan Y
    Eur J Med Chem; 2022 Jul; 237():114381. PubMed ID: 35447433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of osimertinib to discover new potent EGFR
    Xi XX; Zhao HY; Mao YZ; Xin M; Zhang SQ
    Eur J Med Chem; 2023 Dec; 261():115865. PubMed ID: 37839342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.
    Zuo Y; Long Z; Li R; Le Y; Zhang S; He H; Yan L
    Eur J Med Chem; 2024 Feb; 265():116106. PubMed ID: 38169271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
    Lim SM; Fujino T; Kim C; Lee G; Lee YH; Kim DW; Ahn JS; Mitsudomi T; Jin T; Lee SY
    Clin Cancer Res; 2023 Aug; 29(16):3004-3016. PubMed ID: 37249619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S.
    Wang TH; Leu YL; Chen CC; Li HJ; Yang SC; Huang KY; Chen CY
    Phytother Res; 2022 May; 36(5):2116-2126. PubMed ID: 35229911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.
    Dou D; Wang J; Qiao Y; Wumaier G; Sha W; Li W; Mei W; Yang T; Zhang C; He H; Wang C; Chu L; Sun B; Su R; Ma X; Gong M; Xie L; Jiang W; Diao Y; Zhu L; Zhao Z; Chen Z; Xu Y; Li S; Li H
    Eur J Med Chem; 2022 Dec; 244():114856. PubMed ID: 36279692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple
    Zheng Q; Chen D; Wang X; Yang Y; Zhao S; Dong X; Ma C; Zhang X; Duan H; Sun Y; Zheng S
    Ann Transl Med; 2022 Jun; 10(12):696. PubMed ID: 35845484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.